J. Fontcuberta

J. Fontcuberta, A. Gómez-Outes, E. Rocha, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study.

J. Fontcuberta, J. Mateo, E. Muñiz‐Díaz, 1995, The Journal of thoracic and cardiovascular surgery.

Ectopic Transcript Analysis Indicates that Allelic Exclusion is an Important Cause of Type I Protein C Deficiency in Patients with Nonsense and Frameshift Mutations in the PROC Gene

X. Estivill, D. Cooper, V. Kakkar, 1996, Thrombosis and Haemostasis.

Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.

J. Fontcuberta, J. Souto, A. Oliver, 2003, Haematologica.

Elevated Levels of Plasmin-α2 Antiplasmin Complexes in Unstable Angina

A. Bayés‐Genís, A. Bayés de Luna, J. Guindo, 1999, Thrombosis and Haemostasis.

A SEQUENCE VARIATION SCAN OF THE COAGULATION FACTOR ( F ) VIII STRUCTURAL GENE AND ASSOCIATIONS WITH PLASMA FVIII ACTIVITY ( FVIII : C ) LEVELS

L. Almasy, J. Blangero, A. Buil, 2007 .

A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

L. Almasy, J. Blangero, A. Buil, 2007, Blood.

The c.1787G>T and c.1787G>A Mutations are not Found in the Prothrombin Gene in a Spanish Population

J. Fontcuberta, J. Souto, J. Mateo, 2017 .

Thromboplastin-thrombomodulin-mediated time: a new global test sensitive to protein S deficiency and increased levels of factors II, V, VII and X.

J. Fontcuberta, J. Mateo, M. Borrell, 2002, Haematologica.

Association after linkage analysis indicates that homozygosity for the 46C→T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis

J. Fontcuberta, J. Souto, J. Soria, 2004, Thrombosis and Haemostasis.

Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels

J. Martí-Fàbregas, J. Fontcuberta, J. Souto, 2003, Stroke.

Identiﬁcation of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study

L. Almasy, A. Buil, J. Peden, 2009 .

134 Pro-fibrinolytic activity associated heparins on human umbilical vein endothelial cell cultures (huvec) in vitro

J. Fontcuberta, C. Chanquía, A. Fabra, 1988 .

The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism

J. Fontcuberta, J. Soria, J. Mateo, 2005, Thrombosis and Haemostasis.

Hereditary thrombophilia and fetal loss: a prospective follow‐up study

F. Rosendaal, G. Palareti, M. Makris, 2004, Journal of thrombosis and haemostasis : JTH.

Laboratory Evaluation and Clinical Characteristics of 2,132 Consecutive Unselected Patients with Venous Thromboembolism – Results of the Spanish Multicentric Study on Thrombophilia (EMET*-Study)

J. Fontcuberta, J. Mateo, N. Sala, 1997, Thrombosis and Haemostasis.

Increased fetal loss in women with heritable thrombophilia

F. Rosendaal, C. Legnani, M. Makris, 1996, The Lancet.

Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency

J. Corral, V. Vicente, J. Fontcuberta, 2012, Thrombosis and Haemostasis.

AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

J. González-Porras, F. España, A. Estellés, 2008, Haematologica.

Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs

E. Tizzano, J. Fontcuberta, J. Mateo, 2006, Thrombosis and Haemostasis.

Homozygosity of the T allele of the 46 C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population.

J. Fontcuberta, J. Soria, J. Mateo, 2004, Haematologica.

Adverse reaction to streptokinase with multiple systemic manifestations

J. Fontcuberta, I. Montserrat, R. Lamich, 1995, Pharmacy World and Science.

Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project.

J. Fontcuberta, J. Souto, J. Mateo, 2020, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Enhanced risk of thrombotic disease in patients with acquired vitamin B12 and/or folate deficiency: role of hyperhomocysteinemia

J. Fontcuberta, G. Perea, Á. Remacha, 2002, Annals of Hematology.

VAMP8 and serotonin transporter levels are associated with venous thrombosis risk in a Spanish female population. Results from the RETROVE Project.

J. Fontcuberta, J. Souto, J. Mateo, 2019, Thrombosis research.

Massive Pulmonary Embolism: Short-Term Effects of Thrombolytic Treatment

Jordi Félez, J. Fontcuberta, M. Pagès, 1986, Angiology.

IgM anti-protein S antibodies as a risk factor for venous thrombosis

J. Fontcuberta, J. Mateo, A. Santamaría, 2008, Haematologica.

Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease

J. Fontcuberta, J. Mateo, J. Souto, 1995, Digestive Diseases and Sciences.

Lack of association between venous thrombosis and subsequent malignancy in a retrospective cohort study in young patients

J. Fontcuberta, J. Souto, J. Mateo, 1999, American journal of hematology.

Short closure time values in PFA-100® are related to venous thrombotic risk. Results from the RETROVE Study.

J. Fontcuberta, J. Souto, J. Soria, 2018, Thrombosis Research.

Association of functional thrombin‐activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population

J. Fontcuberta, J. Souto, J. Mateo, 2004, American journal of hematology.

A boy with venous thrombosis, homozygous for factor V Leiden, prothrombin G20210A and MTHFR C667t mutations, but belonging to an asymptomatic family.

J. Fontcuberta, J. Soria, C. Vallvé, 2000, Haematologica.

Short-course thrombolysis as the first line of therapy for cardiac valve thrombosis.

F. Carreras, J. Fontcuberta, J. Mateo, 1998, The Journal of thoracic and cardiovascular surgery.

Low‐molecular‐weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study

J. Fontcuberta, A. Santamaría, A. Gómez-Outes, 2006, International journal of clinical practice.

Fibrinolysis changes in normal pregnancy

J. Bellart, J. Fontcuberta, L. Cabero, 1997, Journal of perinatal medicine.

Low levels of plasminogen activator inhibitor type 1 in patients with inflammatory bowel disease

J. Fontcuberta, J. Mateo, J. Souto, 1994 .

Effects of linoleic and oleic acid anilides on prostacyclin synthesis and fibrinolytic profile of human endothelial cells in culture: relevance to the toxic oil syndrome.

J. Fontcuberta, C. Chanquía, L. Vila, 1993, Toxicology.

Serial measurements of a plasma prostacyclin inhibitor in a patient with recurrent abortions and lupus anticoagulant; a case report.

J. Fontcuberta, L. Cabero, M. Borrell, 1988, European journal of obstetrics, gynecology, and reproductive biology.

The V617F mutation of JAK2 is very uncommon in patients with thrombosis.

J. Fontcuberta, J. Mateo, Á. Remacha, 2007, Haematologica.

Antiphospholipid antibodies in inflammatory bowel disease

J. Freyssinet, R. Baumann, J. Fontcuberta, 1995, Digestive Diseases and Sciences.

SUCCESSFUL TREATMENT OF PROSTHETIC HEART-VALVE THROMBOSIS WITH HIGH SHORT-TERM DOSES OF STREPTOKINASE

J. Fontcuberta, J. Llobet, M. Cladellas, 1988, The Lancet.

Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.

J. Fontcuberta, J. Mateo, A. Martínez-Rubio, 2004, Haematologica.

Erythromycin-oral anticoagulants interaction.

Jordi Félez, J. Fontcuberta, E. Grau, 1986, Archives of internal medicine.

Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.

R. Antonijoan, J. Fontcuberta, M. Borrell, 2009, International journal of clinical pharmacology and therapeutics.

Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.

J. Fontcuberta, F. Depasse, M. Borrell, 2003, Thrombosis research.

Coagulation and Fibrinolysis Parameters in Normal Pregnancy and in Gestational Diabetes

E. Carreras, J. Bellart, J. Fontcuberta, 1998, American journal of perinatology.

Low ADAMTS13 levels are associated with venous thrombosis risk in women.

J. Fontcuberta, J. Souto, J. Mateo, 2017, Thrombosis research.

Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin.

J. Fontcuberta, J. Souto, J. Mateo, 2000, Haematologica.

Rapid identification of female haemophilia A carriers with deletions in the factor VIII gene by quantitative Real-Time PCR analysis

M. Barceló, M. Baiget, E. Tizzano, 2005, Thrombosis and Haemostasis.

The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.

J. Fontcuberta, J. Souto, J. Mateo, 2000, Haematologica.

Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers--a first-time-in-human single ascending dose study.

R. Antonijoan, J. Fontcuberta, I. Gich, 2011, Thrombosis research.

Homozygosity of the T Allele of the 46 C→T Polymorphism in the F12 Gene Is a Risk Factor for Ischemic Stroke in the Spanish Population

J. Martí-Fàbregas, J. Fontcuberta, J. Souto, 2004, Stroke.

Thrombolysis as the first line of therapy for cardiac valve thrombosis.

J. Fontcuberta, J. Souto, J. Mateo, 1993, Circulation.

Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation.

J. Fontcuberta, F. Velasco, C. López-Pedrera, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia.

J. Fontcuberta, J. Mateo, M. Borrell, 1995, Thrombosis research.

Coagulation and Fibrinolysis Parameters in Normal and in Hypertensive Pregnancies

J. Bellart, J. Fontcuberta, L. Cabero, 1998 .

PS levels are not influenced by the endogenous estradiol concentration.

J. Fontcuberta, L. Falkon, M. Gari, 1996, Thrombosis and haemostasis.

Severe bleeding in a patient with spontaneous factor VIII inhibitor and acute exacerbation of chronic pancreatitis

J. Fontcuberta, J. Mateo, C. Martinez, 1996, Intensive Care Medicine.

Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis.

L. Almasy, J. Blangero, J. Fontcuberta, 2000, Blood.

Genetic determinants of normal variation in coagulation factor (F) IX levels: genome‐wide scan and examination of the FIX structural gene

L. Almasy, A. Buil, M. Lathrop, 2006, Journal of thrombosis and haemostasis : JTH.

Sequence variation and genetic evolution at the human F12 locus: mapping quantitative trait nucleotides that influence FXII plasma levels.

L. Almasy, J. Blangero, A. Buil, 2010, Human molecular genetics.

Coagulation and Fibrinolytic Parameters in Normal Pregnancy and in Pregnancy Complicated by Intrauterine Growth Retardation

E. Carreras, J. Bellart, J. Fontcuberta, 1998, American journal of perinatology.

Sex-Specific Regulation of Mitochondrial DNA Levels: Genome-Wide Linkage Analysis to Identify Quantitative Trait Loci

L. Almasy, J. Blangero, A. Buil, 2012, PloS one.

Quantitative and qualitative congenital deficiency of antithrombin III: A new molecular variant called at III - Barcelona 2

Jordi Félez, J. Fontcuberta, E. Grau, 1988 .

AT III Barcelona: A Familial Quantitative-Qualitative AT III Deficiency

Jordi Félez, J. Fontcuberta, E. Grau, 1988, Thrombosis and Haemostasis.

Molecular analysis of multiple genetic variants in Spanish FXII-deficient families

J. Fontcuberta, J. Soria, E. Martínez-Marchán, 2007, Haematologica.

217 The fibrinolytic system in nephrotic syndrome (NS)

J. Fontcuberta, E. Grau, A. Oliver, 1988 .

Dysfunctional Activated Protein C (PC Cádiz) in a Patient with Thrombotic Disease

Jordi Félez, J. Fontcuberta, K. Bauer, 1987, Thrombosis and Haemostasis.

Plasma and Urinary Heparin Cofactor II Levels in Patients with Nephrotic Syndrome

J. Ballarín, Jordi Félez, P. Barceló, 1988, Thrombosis and Haemostasis.

Molecular characterization of antithrombin Barcelona-2: 47 arginine to cysteine.

R. Carrell, J. Fontcuberta, M. Owen, 1989, Thrombosis Research.

Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis.

J. González-Porras, J. Corral, V. Vicente, 2007, Blood.

Multiplex assay for genetic testing of thrombophilia: a method for routine clinical care

José Manuel Soria, Mónica López, R Cornudella, 2007, Journal of clinical laboratory analysis.

A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.

L. Almasy, J. Blangero, A. Buil, 2003, Blood.

ThrombosisMolecular Basis of Disease

J. Fontcuberta, J. Soria, 2005 .

New approaches and future prospects for evaluating genetic risk of thrombosis.

J. Fontcuberta, J. Soria, 2005, Haematologica.

Optimization of a simple and rapid single‐strand conformation analysis for detection of mutations in the PROS1 gene: Identification of seven novel mutations and three novel, apparently neutral, variants

X. Estivill, M. Morell, J. Fontcuberta, 2000, Human mutation.

Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis

F. España, A. Estellés, F. Marín, 2009, Thrombosis and Haemostasis.

Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)

F R Rosendaal, F E Preston, F. Rosendaal, 2005, Journal of thrombosis and haemostasis : JTH.

Severe Homozygous Protein C Deficiency: Identification of a Splice Site Missense Mutation (184, Q → H) in Exon 7 of the Protein C Gene

X. Estivill, J. Fontcuberta, J. Soria, 1994, Thrombosis and Haemostasis.

Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.

J. Fontcuberta, M. Borrell, I. Coll, 1990, Haemostasis.

Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency

J. Corral, V. Vicente, J. Fontcuberta, 2012, Thrombosis and Haemostasis.

New biological concepts on coagulation inhibitors

J. Fontcuberta, N. Sala, M. Rutllant, 2005, Intensive Care Medicine.

A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis.

J. González-Porras, J. Corral, V. Vicente, 2006, Blood.

[Morbidity and mortality in patients treated with oral anticoagulants].

J. Fontcuberta, J. Reverter, J. César, 2007, Revista espanola de cardiologia.

Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project.

L. Almasy, J. Blangero, A. Buil, 2003, Thrombosis and haemostasis.

Higher risk of ischaemic stroke associated with factor XI levels in dyslipidaemic patients

J. Martí-Fàbregas, J. Fontcuberta, J. Mateo, 2007, International journal of clinical practice.

A Genome-Wide Association Study of the Protein C Anticoagulant Pathway

L. Almasy, A. Buil, M. Lathrop, 2011, PloS one.

A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels

L. Almasy, J. Blangero, A. Buil, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Complexity of the genetic contribution of different thrombotic risk factors in a Spanish thrombophilic family

J. Fontcuberta, A. Santamaría, I. Tirado, 2005, Thrombosis and Haemostasis.

Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis

L. Ramón, F. España, A. Estellés, 2008, British journal of haematology.

Platelet count and plateletcrit are associated with an increased risk of venous thrombosis in females. Results from the RETROVE study.

J. Fontcuberta, J. Souto, J. Soria, 2017, Thrombosis research.

Late hemorrhagic disease of the newborn as a cause of intracerebral bleeding

J. Fontcuberta, A. Altés, P. Solves, 1997, Annals of Hematology.

Genetic determinants of platelet large-cell ratio, immature platelet fraction, and other platelet-related phenotypes.

J. Fontcuberta, J. Souto, J. Soria, 2015, Thrombosis research.

Heparin-induced thrombocytopenia and heart operation: management with tedelparin.

J. Fontcuberta, A. Altés, M. Gari, 1995, The Annals of thoracic surgery.

In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.

J. Fontcuberta, I. Gich, L. Falkon, 1998, Thrombosis research.

LUPUS ANTICOAGULANT, RECURRENT ABORTION, AND PROSTACYCLIN PRODUCTION BY CULTURED SMOOTH MUSCLE CELLS

J. Fontcuberta, M. Borrell, L. Vila, 1983, The Lancet.

Genomewide linkage analysis of soluble transferrin receptor plasma levels

L. Almasy, J. Blangero, A. Buil, 2005, Annals of Hematology.

Protein S gene analysis reveals the presence of a cosegregating mutation in most pedigrees with type I but not type III PS deficiency

X. Estivill, M. Morell, J. Fontcuberta, 1999, Human mutation.

Pharmacokinetics and Tolerability of a New Low Molecular Mass Heparin (RO-11) in Healthy Volunteers – A Dose-Finding Study within the Therapeutical Range

J. Fontcuberta, M. Barbanoj, L. Falkon, 1997, Thrombosis and Haemostasis.

Fibrinolytic abnormalities. A Spanish multicenter study ebt.I on 443 patients with venous thromboembolic disease.

Jordi Félez, J. Fontcuberta, N. Sala, 1992, Thrombosis research.

Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA

J. Montaner, J. Álvarez-Sabín, J. Martí-Fàbregas, 2005, Neurology.

Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)--a three way cross-over study in healthy volunteers.

R. Antonijoan, J. Fontcuberta, M. Barbanoj, 1995, Thrombosis research.

Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family

J. Fontcuberta, J. Mateo, A. Santamaría, 2005, Thrombosis and Haemostasis.

Protein C Levels Are Regulated by a Quantitative Trait Locus on Chromosome 16: Results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project

L. Almasy, J. Blangero, A. Buil, 2004, Arteriosclerosis, thrombosis, and vascular biology.

A Quantitative Trait Locus Influencing Free Plasma Protein S Levels on Human Chromosome 1q: Results From the Genetic Analysis of Idiopathic Thrombophilia (GAIT) Project

L. Almasy, J. Blangero, M. Lathrop, 2003, Arteriosclerosis, Thrombosis and Vascular Biology.

Homozygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism.

J. Fontcuberta, J. Souto, J. Soria, 1999, Haematologica.

Evolution of leukotriene B4, peptide leukotrienes, and interleukin‐8 plasma concentrations in patients at risk of acute respiratory distress syndrome and with acute respiratory distress syndrome: Mortality prognostic study

J. Fontcuberta, J. Mancebo, J. Mateo, 2000, Critical care medicine.

Influence of Age, Gender and Lifestyle in Lymphocyte Subsets: Report from the Spanish Gait-2 Study

J. Fontcuberta, J. Soria, A. Martinez-Perez, 2012, Acta Haematologica.

Normalisation of Tissue Factor Pathway Inhibitor Activity after Glycaemic Control Optimisation in Type 1 Diabetic Patients

A. de Leiva, M. Rigla, J. Fontcuberta, 2000, Thrombosis and Haemostasis.

Fibrinolytic therapy for superior vena cava and right atrial thrombosis: diagnosis and follow-up with biplane transesophageal echocardiography.

F. Carreras, A. Bayés de Luna, J. Guindo, 1992, American heart journal.

Familial thrombophilia and lifetime risk of venous thrombosis

F R Rosendaal, F E Preston, F. Rosendaal, 2004, Journal of thrombosis and haemostasis : JTH.

Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment.

R. Antonijoan, M. Ballester, J. Fontcuberta, 2014, Thrombosis research.

Detection of two new polymorphisms by PCR-SSCP analysis of the histidine-rich glycoprotein gene in three families with abnormal plasma HRG levels

S. Wakabayashi, J. Fontcuberta, T. Koide, 1997 .

Coagulation Disorders in the Adult Respiratory Distress Syndrome

A. Artigas, J. Fontcuberta, J. Castella, 1985 .

A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project.

L. Almasy, J. Blangero, A. Buil, 2005, American journal of human genetics.

J. Fontcuberta, J. Souto, J. Soria, 2016, Blood cells, molecules & diseases.

Presentation of an acquired factor VIII inhibitor with a muscular haematoma mimicking a deep venous thrombosis in a patient with breast cancer.

J. Fontcuberta, J. Mateo, J. Cruz, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Carotid thrombosis after in vitro fertilization: a relatively new thrombotic complication in women

J. Fontcuberta, J. Mateo, A. Santamaría, 2008, British journal of haematology.

Genetic and environmental factors influencing the human factor H plasma levels

L. Almasy, J. Blangero, A. Buil, 2004, Immunogenetics.

Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study.

L. Almasy, A. Buil, J. Peden, 2009, Blood.

C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies.

L. Almasy, A. Buil, S. Blankenberg, 2010, Blood.

The effect of endogenous oestradiol levels on protein S concentration during a menstrual cycle and after GnRH analogues and gonadotropin therapy

J. Fontcuberta, A. Oliver, L. Falkon, 1995, British journal of haematology.

Physical training decreases plasma thrombomodulin in Type I and Type II diabetic patients

A. de Leiva, M. Rigla, J. Fontcuberta, 2001, Diabetologia.

Combined cis-regulator elements as important mechanism affecting FXII plasma levels.

L. Almasy, J. Blangero, J. Fontcuberta, 2010, Thrombosis research.

Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses.

J. Fontcuberta, M. Barbanoj, J. Amiral, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels

J. Blangero, A. Buil, M. Lathrop, 2008, Human Genetics.

Diagnostic yield of prothrombotic state studies in cryptogenic stroke

J. Martí-Fàbregas, J. Fontcuberta, J. Martí-Vilalta, 2006, Acta neurologica Scandinavica.

An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient.

J. Fontcuberta, M. Borrell, R. Felices, 2007, Haematologica.

A genomewide study of body mass index and its genetic correlation with thromboembolic risk

A. Buil, J. Fontcuberta, J. Souto, 2014, Thrombosis and Haemostasis.

Functional analysis of the genetic variability in the F7 gene promoter.

José Manuel Soria, John Blangero, Laura Almasy, 2007, Atherosclerosis.

The F7 Gene and Clotting Factor VII Levels: Dissection of a Human Quantitative Trait Locus

L. Almasy, J. Blangero, J. Fontcuberta, 2005, Human biology.

Identification of a large deletion and three novel mutations in exon 13 of the factor V gene in a Spanish family with normal factor V coagulant and anticoagulant properties

L. Almasy, J. Blangero, J. Fontcuberta, 2002, Human Genetics.

A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease.

L. Almasy, J. Blangero, A. Buil, 2002, American journal of human genetics.

Patients with venous thromboembolism have a lower APC response than controls. Should this be regarded as a continuous risk factor for venous thrombosis?

J. Fontcuberta, J. Souto, J. Mateo, 1999, Haematologica.

Floating Feature Selection for multiloci association of quantitative traits in sib-pairs analysis

Pere Caminal, Alexandre Perera-Lluna, Helena Brunel, 2008, 2008 8th IEEE International Conference on BioInformatics and BioEngineering.

Human F7 sequence is split into three deep clades that are related to FVII plasma levels

L. Almasy, J. Blangero, J. Bertranpetit, 2006, Human Genetics.

Thromboplastin-thrombomodulin-mediated Time and Serum Folate Levels Are Genetically Correlated with the Risk of Thromboembolic Disease: Results from the GAIT Project

L. Almasy, J. Blangero, J. Fontcuberta, 2002, Thrombosis and Haemostasis.

Elevated levels of plasmin-alpha2 antiplasmin complexes in unstable angina.

A. Bayés‐Genís, A. Bayés de Luna, J. Guindo, 1999, Thrombosis and haemostasis.

Hemostatic disturbances in acute ischemic stroke: a study of 86 patients.

J. Fontcuberta, J. Martí-Vilalta, J. Mateo, 1995, Acta haematologica.

Bemiparin Versus Unfractionated Heparin as Bridging Therapy in the Perioperative Management of Patients on Vitamin K Antagonists: The BERTA Study

J. Fontcuberta, A. Santamaría, E. Pina, 2013, Clinical Drug Investigation.

Heparin cofactor II: a new marker for pre-eclampsia.

J. Bellart, J. Fontcuberta, L. Cabero, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Heritability of plasma concentrations of activated protein C in a Spanish population

A. Buil, F. España, A. Estellés, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Genetic risk factors for thrombosis in a Basque population and its possible contribution to the analysis of a complex disease such as thrombophilia.

M. Tejada, M. Baiget, J. Fontcuberta, 2001, Haematologica.

Genetic determinants of 5-lipoxygenase pathway in a Spanish population and their relationship with cardiovascular risk.

A. Buil, J. Fontcuberta, J. Souto, 2012, Atherosclerosis.

Heritability of Thromboxane A2 and Prostaglandin E2 Biosynthetic Machinery in a Spanish Population

A. Buil, J. Fontcuberta, J. Souto, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Genetic Regulation of Plasma Levels of Vitamin K-dependent Proteins Involved in Hemostasis

L. Almasy, J. Blangero, J. Fontcuberta, 2001, Thrombosis and Haemostasis.

Genetic determinants of variation in the plasma levels of the C4b-binding protein (C4BP) in Spanish families

L. Almasy, J. Blangero, A. Buil, 2003, Immunogenetics.

Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator

J. Montaner, J. Martí-Fàbregas, M. Millán, 2006, Stroke.

[Pregnancy and thrombophilia in women with congenital deficit of antithrombin III, protein C, protein S or plasminogen: analysis of 39 cases].

J. Fontcuberta, J. Mateo, M. Borrell, 1993, Medicina clínica (Ed. impresa).

Antithrombin Cambridge II mutation as a risk factor to develop cerebral venous thrombosis

J. Fontcuberta, A. Santamaría, I. Tirado, 2008, Thrombosis and Haemostasis.

What is the clinical impact of low plasminogen activator inhibitor‐1 (PAI‐1) activity? A case report and study of the incidence of low PAI‐1 antigen in a healthy population

J. Fontcuberta, J. Mateo, A. Santamaría, 2007, Journal of thrombosis and haemostasis : JTH.

C 4 BPB / C 4 BPA is a new susceptibility locus for venous thrombosis with unknown protein S – independent mechanism : results from genome-wide association and gene expression analyses followed by case-control studies

L. Almasy, A. Buil, S. Blankenberg, 2010 .

Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.

L. Almasy, L. Almasy, J. Blangero, 2000, American journal of human genetics.

Spontaneous Retroperitoneal Hemorrhage During Oral Anticoagulant Therapy

Jordi Félez, J. Fontcuberta, P. Domingo, 1985, Archives of Internal Medicine.

Skin Necrosis at the Injection Site Induced by Low-Molecular-Weight Heparin: Case Report and Review

J. Fontcuberta, J. Souto, J. Mateo, 1998, Dermatology.

Hemostasis, Thrombosis, and Vascular Biology

J. Corral, V. Vicente, J. Fontcuberta, 2006 .

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

M. Margaglione, E. Grandone, J. Corral, 2005 .

Genetic determinants of hemostasis phenotypes in Spanish families.

L. Almasy, J. Blangero, J. Fontcuberta, 2000, Circulation.

The influence of low protein S plasma levels in young women, on the definition of normal range.

J. Fontcuberta, M. Borrell, C. Vallvé, 1994, Thrombosis research.

Lack of Effect of Influenza Vaccine on Anticoagulation by Acenocoumarol

J. Fontcuberta, J. Mateo, A. Sureda, 1993, The Annals of pharmacotherapy.

A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.

L. Almasy, A. Buil, M. Lathrop, 2003 .

The F7 Gene and Clotting Factor VII Levels: Dissection of a Human Quantitative Trait Locus

Juan Carlos Souto, John Blangero, Maria Sabater-Lleal, 2006, Human biology.

Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis

L. Almasy, J. Blangero, J. Fontcuberta, 2000 .

Hemostasis, Thrombosis, and Vascular Biology Patients and Methods Subjects and Phenotypes Table 1. Results from the Linkage Analysis: Apcr with F5 Dna Variants, and Apcr Conditional on the Fvl Mutation

L. Almasy, J. Blangero, A. Buil, 2022 .

Heritability of Hemostasis Phenotypes and Their Correlation with Type 2 Diabetes Status in Mexican Americans

L. Almasy, L. Almasy, J. Blangero, 2005, Human biology.

Genetic correlation between plasma levels of C4BP isoforms containing β chains and susceptibility to thrombosis

L. Almasy, J. Blangero, A. Buil, 2004, Journal of Medical Genetics.

LEVELS OF COAGULATION INHIBITORS AND THROMBIN-ANTITHROMBIN III COMPLEXES IN NORMAL PREGNANCY

J. Bellart, J. Fontcuberta, L. Cabero, 1997 .

[Detection of thrombin-antithrombin complexes in hypercoagulability conditions. Analysis of 182 cases].

J. Fontcuberta, J. Mateo, M. Borrell, 1990, Sangre.

Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time.

L. Almasy, J. Blangero, J. Fontcuberta, 2000, Arteriosclerosis, thrombosis, and vascular biology.

The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms.

H. Augustin, H. Hammes, K. Preissner, 2006, Blood.

Bleeding diathesis associated with beta‐lactam antibiotics

Jordi Félez, J. Fontcuberta, E. Grau, 1990, European journal of haematology.

A Locus on Chromosome 2 Influences Levels of Tissue Factor Pathway Inhibitor: Results From the GAIT study

L. Almasy, A. Buil, M. Lathrop, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels

L. Almasy, J. Blangero, A. Buil, 2008, European Journal of Human Genetics.

Hereditary Macrothrombocytopenia and Pregnancy

J. Fontcuberta, P. Madoz, N. Pujol-Moix, 1996, Thrombosis and Haemostasis.